Well, AGN didn't specify what went wrong in DARPin's trial (did they?) and if they do another phase II with higher dose then the problem is probably that duration of action isn't long enough to compete with marketed anti-VEGF's. I am surprised, I was quite optimistic about this program.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.